(Q34488671)

English

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Elizabeth Fox

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Richard Aplenc

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Rochelle Bagatell

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Meredith K Chuk

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Eva Dombi

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Wendy Goodspeed

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Anne Goodwin

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Marie Kromplewski

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Nalini Jayaprakash

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Marcelo Marotti

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Kathryn H Brown

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Barbara Wenrich

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter C Adamson

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Brigitte C Widemann

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Frank M Balis

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

8 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

5174-5181

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

A comprehensive review of spontaneous pneumothorax complicating sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

6 July 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

27 October 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020690

27 October 2018

Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Con

1 reference

https://pubmed.ncbi.nlm.nih.gov/21060028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21060028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.30.9674

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34488671&oldid=2143274934"